C90.00

Multiple myeloma not having achieved remission

## Overview: Multiple Myeloma Not Having Achieved Remission (C90.00) Multiple myeloma (MM) not having achieved remission (ICD-10 code C90.00) describes a state where a patient with previously diagnosed multiple myeloma has undergone treatment but has failed to meet the established criteria for any level of remission. This indicates persistent active disease despite therapeutic interventions, suggesting either primary refractory disease or insufficient response to therapy. It is a critical classification for guiding further management strategies. ### Pathophysiology Multiple myeloma is a malignant plasma cell disorder originating in the bone marrow. It is characterized by the clonal proliferation of abnormal plasma cells, which produce a monoclonal immunoglobulin (M-protein). The pathophysiology of persistent disease (not having achieved remission) is fundamentally the same as de novo MM but with added layers of complexity, primarily related to drug resistance and clonal evolution. Myeloma cells thrive within the bone marrow microenvironment, interacting with stromal cells, osteoclasts, and endothelial cells. This interaction fosters cell growth, survival, and resistance to apoptosis through various signaling pathways (e.g., NF-κB, MAPK, PI3K/Akt, JAK/STAT). Genetic abnormalities, such as translocations t(4;14), t(14;16), t(11;14), and deletions of chromosome 17p, are common and contribute to disease aggressiveness and therapeutic resistance. In cases of not achieving remission, the disease may have selected for clones with enhanced resistance mechanisms, such as increased drug efflux pump activity, mutations in drug targets, or upregulation of anti-apoptotic proteins. The persistent burden of malignant plasma cells leads to the characteristic end-organ damage, including bone destruction (lytic lesions, osteopenia), hypercalcemia, renal insufficiency, and anemia, known collectively as the "CRAB" features. ### Clinical Presentation Patients with multiple myeloma not having achieved remission will typically present with ongoing or worsening symptoms related to the underlying disease. These manifestations are largely a continuation or exacerbation of the CRAB features: * **Hypercalcemia:** Often leads to fatigue, weakness, confusion, polyuria, polydipsia, and constipation. * **Renal Impairment:** Can manifest as fatigue, peripheral edema, decreased urine output, and electrolyte disturbances, primarily due to tubular damage from M-protein light chains (myeloma kidney). * **Anemia:** Results in severe fatigue, pallor, weakness, and shortness of breath, stemming from bone marrow infiltration by plasma cells and suppression of normal hematopoiesis. * **Bone Lesions:** Cause severe and persistent bone pain, pathological fractures (vertebral compression fractures being common), and potentially spinal cord compression, leading to neurological deficits. Other symptoms may include recurrent infections due to immunoparesis, weight loss, and less commonly, symptoms of hyperviscosity syndrome (e.g., headaches, visual disturbances, confusion) or peripheral neuropathy. The key differentiating factor from newly diagnosed MM is the context of these symptoms occurring or persisting despite a course of treatment. ### Diagnostic Criteria The diagnosis of "multiple myeloma not having achieved remission" is a status determination following therapy, rather than an initial diagnosis. It is based on the failure to meet the International Myeloma Working Group (IMWG) criteria for remission after treatment. The IMWG definitions of remission states are: * **Complete Remission (CR):** Negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, and <5% plasma cells in bone marrow aspirate. * **Stringent Complete Remission (sCR):** CR plus normal free light chain (FLC) ratio and absence of clonal cells by multiparametric flow cytometry. * **Very Good Partial Remission (VGPR):** Serum and urine M-protein detectable by immunofixation but not electrophoresis, or >90% reduction in serum M-protein plus urine M-protein level <100 mg/24 hours. * **Partial Remission (PR):** ≥50% reduction in serum M-protein and ≥90% reduction in urine M-protein (if baseline ≥200 mg/24 hours), and ≥50% reduction in soft tissue plasmacytomas. If a patient's disease markers (M-protein levels, bone marrow plasma cell percentage, presence of plasmacytomas, or CRAB features) do not improve sufficiently to meet at least the PR criteria following therapy, they are classified as having not achieved remission (refractory disease). Laboratory tests include serial monitoring of serum and urine M-protein (electrophoresis and immunofixation), serum free light chains, quantitative immunoglobulins, CBC, comprehensive metabolic panel (including calcium and creatinine). Imaging studies (e.g., skeletal survey, MRI, PET/CT) are used to assess bone lesions and extramedullary disease. Bone marrow aspirate and biopsy are essential to quantify plasma cell infiltration and perform cytogenetic analysis. ### Standard of Care The standard of care for multiple myeloma not having achieved remission involves a tailored approach based on prior treatments, patient fitness, and the specific characteristics of the disease. The goal is to achieve the deepest possible response, improve quality of life, and prolong survival. Treatment strategies typically involve combination regimens utilizing novel agents, many of which are different from or in different combinations than initial therapy. Key therapeutic classes include: * **Proteasome Inhibitors (PIs):** Bortezomib, carfilzomib, ixazomib. * **Immunomodulatory Drugs (IMiDs):** Lenalidomide, pomalidomide. * **Monoclonal Antibodies (mAbs):** Daratumumab and isatuximab (anti-CD38), elotuzumab (anti-SLAMF7). * **Corticosteroids:** Dexamethasone is a backbone of many regimens. * **Alkylating Agents:** Cyclophosphamide, melphalan. * **Exportin 1 (XPO1) Inhibitors:** Selinexor. * **Histone Deacetylase (HDAC) Inhibitors:** Panobinostat. * **Bispecific Antibodies:** Teclistamab (BCMA/CD3), talquetamab (GPRC5D/CD3). * **Chimeric Antigen Receptor (CAR) T-cell Therapy:** Idecabtagene vicleucel, ciltacabtagene autoleucel (targeting BCMA). For eligible patients, autologous stem cell transplant (ASCT) may be reconsidered in the relapsed/refractory setting, often following a salvage regimen. Supportive care is paramount and includes bisphosphonates for bone disease, pain management, erythropoiesis-stimulating agents for anemia, infection prophylaxis, and vigilant management of renal complications. Participation in clinical trials is often a crucial consideration for patients with refractory disease, offering access to cutting-edge therapies.

Clinical Symptoms

  • Persistent or worsening bone pain (e.g., back, ribs, hips)
  • Pathological fractures
  • Anemia (fatigue, weakness, pallor, shortness of breath)
  • Renal dysfunction (edema, reduced urine output, electrolyte imbalances)
  • Hypercalcemia (fatigue, confusion, constipation, polyuria, nausea)
  • Recurrent infections (pneumonia, urinary tract infections)
  • Weight loss
  • Neuropathy (numbness, tingling in extremities)
  • Spinal cord compression (weakness, sensory loss, bladder/bowel dysfunction)
  • Extramedullary plasmacytomas (soft tissue masses, organ dysfunction depending on location)
  • Bleeding diathesis (rare, due to platelet dysfunction or hyperviscosity)
  • Headache and visual disturbances (due to hyperviscosity syndrome)

Common Causes

  • Intrinsic drug resistance of myeloma cells (e.g., due to specific cytogenetic abnormalities like del(17p) or t(4;14))
  • Acquired drug resistance through clonal evolution during therapy
  • Microenvironmental support of myeloma cells by bone marrow stromal cells
  • High tumor burden at initial diagnosis
  • Extramedullary disease
  • Presence of plasma cell leukemia
  • Suboptimal initial therapy regimen
  • Patient non-adherence to treatment
  • High-risk genetic features (e.g., del(17p), t(4;14), 1q gain)

Documentation & Coding Tips

Explicitly document the current disease status as 'not having achieved remission' or 'active multiple myeloma' to support C90.00. Clearly distinguish from conditions in remission.

Example: Patient presents for cycle 5 of Daratumumab, Lenalidomide, and Dexamethasone for active multiple myeloma. Follow-up M-protein electrophoresis shows persistent M-spike at 1.2 g/dL, indicating continued active disease, not in remission. ESR 45, Creatinine 1.8 mg/dL (baseline 1.1). Plan: Continue current regimen. Address chronic kidney disease (N18.9) related to myeloma.

Billing Focus: The explicit statement 'not in remission' or 'active multiple myeloma' is critical for correct coding of C90.00 versus C90.01. Linking associated conditions (e.g., CKD) to the myeloma is crucial for higher reimbursement.

Document all relevant complications and manifestations of multiple myeloma, linking them to the primary diagnosis when clinically appropriate.

Example: 3-month follow-up for multiple myeloma, not in remission. Patient reports worsening lower back pain, confirmed on MRI to be a new L4 vertebral compression fracture due to pathological fracture (M84.58). Hemoglobin remains 8.5 g/dL despite EPO, consistent with anemia of malignancy (D63.0). Plan: Refer to Pain Management for vertebral augmentation, continue EPO and PRBC transfusions as needed.

Billing Focus: Specifying 'pathological fracture' and linking it to multiple myeloma (M84.58) provides higher specificity and justification for procedures. Documenting 'anemia of malignancy' (D63.0) links a common complication directly to the primary diagnosis.

Detail the specific treatment regimen (chemotherapy, radiation, transplant) and the patient's response or lack thereof.

Example: Patient continues on Carfilzomib, Pomalidomide, and Dexamethasone for refractory multiple myeloma, not in remission. While M-spike has stabilized, it has not decreased significantly, and bone marrow biopsy shows >10% plasma cells. Plan: Evaluate for potential stem cell transplant at next visit. Manage chemotherapy-induced peripheral neuropathy (G62.1).

Billing Focus: Documentation of specific chemotherapy agents and the patient's refractoriness or lack of response supports medical necessity for ongoing complex treatments and justifies continued management of a difficult-to-treat condition.

Clearly state the stage of multiple myeloma at diagnosis and any subsequent changes in staging, if applicable.

Example: Patient initially diagnosed with Stage III IgG Kappa Multiple Myeloma, currently not in remission. FISH analysis shows t(4;14) translocation. Disease remains active, with persistent lytic lesions in the skull and vertebrae. Current treatment aims to control disease progression.

Billing Focus: While C90.00 does not directly code stage, detailing the original stage and genetic markers provides crucial context for medical necessity and aligns with clinical guidelines for managing this complex disease, justifying advanced therapies.

Include pertinent laboratory and imaging findings that support the diagnosis of active, not-in-remission multiple myeloma.

Example: Follow-up for C90.00. Labs: M-protein 1.5 g/dL (stable, not resolved), serum free light chains kappa 250 mg/L, lambda 15 mg/L (kappa/lambda ratio 16.7). Imaging: PET scan shows new area of increased uptake in the left iliac crest, concerning for progression. Bone marrow biopsy 2 weeks ago showed 15% clonal plasma cells.

Billing Focus: Specific lab values (M-protein, free light chains, kappa/lambda ratio) and imaging findings (new lesions, increased uptake) are objective evidence of active disease, supporting medical necessity for ongoing monitoring and aggressive treatment.

Relevant CPT Codes

Related Diagnoses

Hierarchy